ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0295

CCL3L3–null Status May Predispose to Systemic Lupus Erythematosus and Non-scarring Alopecia

Eunyoung Lee1, Young-Ho Kim2, Hye Won Sim2, Eun-Kyung Kang2, Yoon-Ho Won2, Esther Park2, Yeong-Wook Song3 and Kyeong-Man Hong2, 1Seoul National University Hospital, Seoul, Republic of Korea, 2National Cancer Center, Ilsan, Kyonggi-do, Republic of Korea, 3Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Seoul, Korea, Republic of Korea

Meeting: ACR Convergence 2020

Keywords: genetics, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The correlation between the copy number variation of CCL3L1 and susceptibility to systemic lupus erythematosus (SLE), rheumatoid arthritis, Kawasaki disease, and HIV infection has been reported. However, the high level of homology (50 – 99%) within the CCL3L gene family has raised questions on the previously reported associations.

Methods: A modified real competitive PCR (mrcPCR) assay for the specific detection of CCL3L1 and CCL3L3 was developed with consideration of high homology within the CCL3L gene family. The CCL3L1 and CCL3L3 copy numbers were determined in 373 SLE patients and 358 age- and sex-matched controls by the mrcPCR assay and their associations with SLE or SLE manifestations were analyzed.

Results: CCL3L1 or CCL3L3 copy numbers did not have any significant correlation with the prevalence of SLE. However, the absence of the CCL3L3 gene or CCL3L3-null status was observed only in SLE patients (N = 19, P < 0.0001), whereas CCL3L1-null status was not significantly associated with SLE (P = 1.000). In addition, CCL3L3-null status was marginally associated (P = 0.053), and lower CCL3L3 copy status (0 or 1) was significantly associated (P = 0.013) with non-scarring alopecia in patients with SLE.

Conclusion: The CCL3L3-null status may predispose to SLE, and low CCL3L3-copy status was significantly associated with non-scarring alopecia in SLE patients.

Association of CCL3L3-null status with SLE. A. No significant association of CCL3L1 copy number with SLE. B. No significant association of CCL3L3 copy number with SLE. C. No significant association of the copy number ratio of CCL3L3/CCL3L1 with SLE. D. No significant association of the copy number sum of CCL3L3 and CCL3L1 with SLE. Statistical tests for A-D were performed by the Mann-Whitney test. E. No significant association of CCL3L1-null status with SLE (Fisher’s exact test) F. Significant association of CCL3L3-null status with SLE (Fisher’s exact test).


Disclosure: E. Lee, None; Y. Kim, None; H. Sim, None; E. Kang, None; Y. Won, None; E. Park, None; Y. Song, None; K. Hong, None.

To cite this abstract in AMA style:

Lee E, Kim Y, Sim H, Kang E, Won Y, Park E, Song Y, Hong K. CCL3L3–null Status May Predispose to Systemic Lupus Erythematosus and Non-scarring Alopecia [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/ccl3l3-null-status-may-predispose-to-systemic-lupus-erythematosus-and-non-scarring-alopecia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ccl3l3-null-status-may-predispose-to-systemic-lupus-erythematosus-and-non-scarring-alopecia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology